The effect of CD33+MDSC-mediated T lymphocyte function on the therapeutic efficacy of 125I particle implantation combined with arterial chemoembolization in the treatment of cervical cancer.
- Author:
Yongjin HU
1
;
Zanhong WANG
2
;
Feng'e LI
3
;
Weihong FENG
3
;
Yupeng WANG
3
Author Information
1. Department of Gynaecologic Oncology, Obstetrics and Gynaecology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032; Department of Oncology, Beichen Hospital Affiliated to Nankai University, Tianjin 300000, China.
2. Department of Gynaecologic Oncology, Obstetrics and Gynaecology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China. *Corresponding author, E-mail: jv7238@sina.com.
3. Department of Oncology, Beichen Hospital Affiliated to Nankai University, Tianjin 300000, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Female;
Uterine Cervical Neoplasms/immunology*;
Middle Aged;
Chemoembolization, Therapeutic/methods*;
Sialic Acid Binding Ig-like Lectin 3/immunology*;
Adult;
T-Lymphocytes/immunology*;
Aged;
Treatment Outcome
- From:
Chinese Journal of Cellular and Molecular Immunology
2025;41(10):905-912
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the expression levels of CD33+ myeloid-derived suppressor cell (MDSC)-mediated T lymphocyte function and related inflammatory factors secreted by T lymphocyte subsets in patients with cervical cancer, and to analyze their correlation with the treatment efficacy of 125I particle implantation combined with arterial chemoembolization, as well as predictive value for treatment outcomes and interaction effects. Methods From January 1st, 2021 to January 1st, 2024, our hospital admitted 152 patients with advanced cervical cancer, who were confirmed by pathological examination. All patients received uterine artery chemoembolization combined with 125I particle implantation. The predictive value of CD33+MDSC levels for clinical treatment response in cervical cancer was assessed using receiver operating characteristic (ROC) curve analysis. Multivariate logistic regression analysis was performed to evaluate both multiplicative and additive interactions between CD33+MDSC and T lymphocytes in predicting clinical treatment failure of cervical cancer. Kaplan Meier method was used to analyze the survival differences between cervical cancer patients with high and low CD33+MDSC expression levels. Results Compared with the effective group, patients in the ineffective group had decreased expression levels of CD3+ T lymphocyte, CD4+ T lymphocyte, interleukin 2 (IL-2) and interferon γ (IFN-γ), while showing increased expression levels of CD33+MDSC, CD8+ T lymphocyte, IL-4 and IL-6, along with increased tumor necrosis factor α (TNF-α) levels, larger maximum tumor diameters, and a higher incidence of lymph node metastasis. The expression levels of CD33+MDSCs demonstrated good predictive performance for treatment efficacy in cervical cancer patients. The high CD33+MDSC expression group had a significantly shorter overall survival (OS) than the low CD33+MDSC expression group (6.0±1.0 months vs. 12.0±1.2 months; t=33.280). The interaction analysis revealed that CD33+MDSCs and CD8+ T lymphocytes were highly expressed, while CD3+ and CD4+ T lymphocytes were lowly expressed, which was associated with an increased risk of clinical treatment failure in cervical cancer patients. Conclusion CD33+MDSCs can inhibit CD3+ and CD4+ T lymphocytes. It can upregulate the expression of CD8+ T lymphocytes, form an immunosuppressive microenvironment, and reduce the treatment response rate of 125I particle implantation combined with arterial chemoembolization. CD33+MDSCs may serve as an independent biomarker for predicting the therapeutic efficacy and poor prognosis.
